Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH
Bank of America Corp DE significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 59.4% in the first quarter, selling over 276,000 shares but still retaining a holding worth approximately $15.8 million. Despite this, institutional investors collectively own 47.53% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27. Recent insider selling has also occurred, with over $29 million worth of shares sold in the last three months, even as the company's stock approaches its 52-week high.
Dianthus Therapeutics director Simon Read sells $326,553 in stock
Dianthus Therapeutics director Simon Read sold 2,778 shares of company stock for $326,553 on August 19, 2026, after exercising stock options under a Rule 10b5-1 trading plan. The sale occurred near the stock's 52-week high, with the company showing a 401% return over the past year. Despite the insider sale, recent news indicates strong analyst confidence due to positive Q2 earnings, the development of DNTH312, and promising clinical trial data for claseprubart.
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH
Eagle Health Investments LP has acquired 131,344 shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) valued at approximately $12.8 million, making it their 20th largest holding. Despite this institutional interest and a "Moderate Buy" consensus rating from analysts, insiders have recently sold a significant amount of stock, totaling nearly $29.6 million. Dianthus Therapeutics reported a quarterly loss but exceeded revenue expectations, and the company is developing complement therapeutics for autoimmune and inflammatory diseases.
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Royal Bank of Canada significantly increased its stake in Dianthus Therapeutics, Inc. by 847.5% in the first quarter, now holding 19,064 shares valued at $1.60 million. Despite the company missing EPS estimates, institutional investors collectively own 47.53% of the stock, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $124.27. However, recent insider selling, including by the CEO and a director, totals approximately $29.6 million over the past 90 days.
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com
Dianthus Therapeutics director Simon Read sold 2,778 shares of the company's stock for $326,553, after exercising options at a lower price, all under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-week high, with InvestingPro suggesting it is overvalued. The company recently reported strong Q2 2026 earnings, announced a new drug development, initiated a Phase 3 trial, and received reiterated "Strong Buy" ratings and increased price targets from several analysts.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts
Dianthus Therapeutics (NASDAQ:DNTH) has received a consensus "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $124.27. Despite shares trading near a 52-week high, the company remains unprofitable, reporting a quarterly loss of $0.90 per share, and insiders have sold approximately $29.3 million worth of shares in the past 90 days. Institutional investors, however, have shown significant activity, with some increasing their stakes in the company.
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH
TimesSquare Capital Management LLC has acquired 166,357 shares of Dianthus Therapeutics (NASDAQ:DNTH) valued at approximately $16.2 million, representing 0.30% of the company. Despite significant insider selling totaling $29.3 million over the past 90 days and a missed EPS consensus, analysts maintain a "Moderate Buy" rating with an average price target of $124.27. Dianthus Therapeutics' stock opened at $114.86, close to its 52-week high, with institutional investors owning 47.53% of the shares.
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH
SCS Capital Management LLC recently acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) worth approximately $914,000, contributing to 47.53% institutional ownership. Despite positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $124.27, company insiders have sold a significant number of shares, valued at about $29.3 million, over the past 90 days. Dianthus Therapeutics also reported a quarterly EPS miss of -$0.90 against an expected -$0.85.
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH
Walleye Capital LLC initiated a new position in Dianthus Therapeutics (NASDAQ:DNTH) worth approximately $1.74 million during the second quarter. Other institutional investors also adjusted their holdings, bringing total institutional ownership to 47.53%. Despite the company reporting an adjusted loss per share that missed estimates, analysts maintain a "Moderate Buy" rating with an average price target of $124.27, reflecting confidence in its future.
Dianthus Therapeutics stock hits 52-week high at 114.64 USD
Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $114.64, trading at $114.68, marking a 441% increase over the past year and 166% year-to-date. This surge follows recent positive developments, including the announcement of second-quarter 2026 earnings, the introduction of a new bifunctional fusion protein DNTH312, and the initiation of a Phase 3 trial for claseprubart. Analysts have responded positively, with multiple firms reiterating strong buy ratings and raising price targets, though InvestingPro suggests the shares may be overvalued.
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $114.64, driven by a 441% increase over the past year and 166% year-to-date. This surge follows positive developments including upward revisions of earnings estimates by analysts, the introduction of a new bifunctional fusion protein DNTH312, and progress in clinical trials for claseprubart in Myasthenia Gravis and CIDP. Despite potential overvaluation according to InvestingPro, analysts maintain strong buy ratings, citing favorable clinical data and market conditions.
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH)
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 1,696,751 shares in Dianthus Therapeutics Inc. (DNTH), representing 3.1% of the company's outstanding common stock. This figure includes 510,400 shares issuable upon the exercise of call options. The filing indicates shared voting and dispositive power over these shares and is an amendment to a Schedule 13G, confirming ownership of less than 5% of the class.
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake
Wellington Management entities have disclosed a passive beneficial ownership stake of approximately 5.9% (3,229,882 shares) in Dianthus Therapeutics (DNTH) through a Schedule 13G filing. The shares are held by clients of various Wellington investment advisers, with Wellington reporting shared voting and dispositive power but no sole voting or dispositive power. No single client holds more than five percent of the class.
Dianthus therapeutics director Simon Read sells $304k in stock
Simon Read, a director at Dianthus Therapeutics Inc. (NASDAQ:DNTH), sold approximately $304,231 worth of common stock on August 10, 2026. This transaction involved the exercise of stock options and subsequent sale of 2,777 shares, executed under a Rule 10b5-1 trading plan. Following these sales, Mr. Read no longer holds direct beneficial ownership in the company, whose stock has seen a 445% gain in the past year but is considered overvalued by InvestingPro.
Dianthus therapeutics director Simon Read sells $304k in stock
Simon Read, a director at Dianthus Therapeutics, sold approximately $304,231 worth of common stock on August 10, 2026, after exercising stock options. These transactions, conducted under a Rule 10b5-1 trading plan, leave Mr. Read with no direct beneficial ownership in the company. The sale occurred while the stock was trading near its 52-week high, following a significant 445% gain over the past year.
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock
Adam M. Veness, SVP of Dianthus Therapeutics (NASDAQ:DNTH), sold over $2.2 million worth of company common stock and acquired $357,599 through option exercises. These transactions occurred on August 7 and 10, 2026, under a pre-established trading plan, as the stock trades near its 52-week high after a significant gain.
Dianthus Therapeutics Insider Sold Shares Worth $844,822, According to a Recent SEC Filing
An insider at Dianthus Therapeutics (DNTH) has sold shares valued at $844,822, as disclosed in a recent SEC filing. This transaction, reported on August 11, 2026, follows another recent insider sale of $2,208,833. Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases, with its lead candidate claseprubart currently in Phase 3 trials.
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock
Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness sold 16,167 shares of the company's stock for approximately $1.78 million, reducing his stake by over 80%. This transaction occurred as the company's shares fell 3.0% to $108.49, following a quarterly earnings report that missed EPS estimates but exceeded revenue forecasts. Despite the insider sale and EPS miss, analyst sentiment remains broadly positive, with a "Moderate Buy" consensus and an average price target of $124.27.
Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics director Anne Mcgeorge sold 7,750 shares of DNTH stock for over $844,000, reducing her direct ownership by 86.11%. Despite the sale, which occurred near the stock's 12-month high, analysts maintain a "Moderate Buy" rating with a consensus price target of $124.27. The company recently reported a quarterly loss but exceeded revenue expectations, with institutional investors holding 47.53% of the stock.
Simon Read Sells 2,777 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics Director Simon Read sold 2,777 shares of the company's stock for over $304,000, reducing his stake by 50%. This transaction occurred as DNTH shares experienced a 3.0% decline following a quarterly earnings report that missed EPS estimates, despite revenue exceeding expectations. Analysts maintain a "Moderate Buy" rating for Dianthus Therapeutics, with an average price target of $124.27.
DNTH insider Adam M. Veness plans Rule 144 sale of 16,167 shares
Adam M. Veness, an insider at Dianthus Therapeutics, Inc. (DNTH), has filed a Rule 144 notice to sell 16,167 common shares valued at $1,760,909.64. The transaction, scheduled for August 10, 2026, involves an exercise of stock options for cash on the same date and will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. This planned sale follows previous 10b5-1 plan sales by Veness in June and August 2026.
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 10, 2026)
Dianthus Therapeutics, Inc. /DE/ filed a Form 144 with the SEC on August 10, 2026, indicating a proposed sale of 5,550 shares of common stock with an aggregate market value of $624,375.00 through Jefferies LLC. The shares were acquired on May 22, 2025, via a stock option exercise. The filing details information about the securities to be sold and the acquisition circumstances.
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
The California State Teachers Retirement System significantly increased its stake in Dianthus Therapeutics (DNTH) by 155.5% in the first quarter, now owning 40,584 shares valued at $3.4 million. Despite this institutional confidence and generally positive analyst ratings, the company faces risks including ongoing losses, missing quarterly EPS expectations, and substantial insider selling. Dianthus Therapeutics focuses on developing complement therapeutics for autoimmune and inflammatory diseases and currently holds a "Moderate Buy" consensus rating among analysts.
Dianthus Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Dianthus Therapeutics Inc is projected to report a loss of 86 cents per share. This information comes from an earnings preview provided by Reuters, accessible through TradingView News. The full article and more content from various news sources are available with an unlimited access subscription on TradingView.
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com
Marino Garcia, CEO of Dianthus Therapeutics (NASDAQ:DNTH), sold 166,000 shares totaling approximately $17.95 million on August 7, 2026, following the exercise of stock options. The sale occurred near the stock's 52-week high after a significant 481% return, aligning with an analyst valuation suggesting the stock is overvalued. Dianthus also recently announced a Phase 3 EMERGE trial and received positive analyst ratings from Raymond James, Guggenheim, and TD Cowen.
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares
Dianthus Therapeutics CEO Marino Garcia sold approximately $17.95 million worth of common stock on August 7, 2026, through a pre-planned trading strategy. This sale occurred while the stock was trading near its 52-week high after a significant 481% return over the past year. Concurrently, Dianthus Therapeutics announced the initiation of its Phase 3 EMERGE trial and received positive analyst ratings from Raymond James, Guggenheim, and TD Cowen.
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 7, 2026)
This article reports on Dianthus Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of 40,000 shares of common stock with an aggregate market value of $4,396,800.00, resulting from the exercise of stock options. The filing has a neutral impact and sentiment according to AI-generated analysis.
Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 million
Dianthus Therapeutics CEO and President Marino Garcia exercised options for 166,000 shares at $8.44 each, increasing his direct holdings. Subsequently, he sold these 166,000 shares at prices ranging from $107.49 to $110.76, reducing his direct common stock holdings to 65,292 shares. The total value of the shares disposed was approximately $17.97 million.
Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics CEO Marino Garcia sold 166,000 shares of the company's stock for approximately $17.95 million, reducing his direct ownership by 71.77%. The sale occurred on August 7th, with shares trading at $108.11 on average. Despite missing recent earnings estimates, the company's stock is near its 12-month high, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27.
Dianthus Therapeutics (DNTH): T. Rowe Price reports 7.1% stake in common stock
T. Rowe Price Investment Management, Inc. has reported a 7.1% stake in Dianthus Therapeutics Inc.'s common stock, totaling 3,888,456 shares. The investment firm holds sole voting power over 3,884,903 shares and sole dispositive power over all 3,888,456 shares. Despite this, T. Rowe Price explicitly denies beneficial ownership and states the securities were acquired and are held in the ordinary course of business, not for influencing control of the issuer.
Dianthus Therapeutics (DNTH): T. Rowe Price reports 12.1% ownership stake
T. Rowe Price Investment Management, Inc. has reported a beneficial ownership stake of 12.1% in Dianthus Therapeutics Inc., amounting to 6,632,303 shares of common stock. The firm maintains sole voting power over 6,454,315 shares and sole dispositive power over all 6,632,303 shares. Despite the filing, T. Rowe Price explicitly denies beneficial ownership, stating the report should not be construed as an admission.
DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125
Raymond James has increased its target price for Dianthus Therapeutics Inc. to $131 from $125. The article, sourced from Reuters, indicates this change in financial outlook for the company. The content primarily highlights this price target adjustment.
Dianthus Therapeutics, Inc. Stock 12‑Month Price Target Raised to $133.79, Implies 21% Upside
The average 12-month price target for Dianthus Therapeutics, Inc. (DNTH) stock has increased from $129.77 to $133.79, according to 14 analysts. This updated target suggests a potential upside of approximately 21% from its August 4th closing price. The consensus rating for DNTH remains a "Buy" from 16 covering analysts.
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH
Dimensional Fund Advisors LP increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 54.5%, purchasing 114,767 additional shares to own a total of 325,440 shares. This move comes despite the company missing its quarterly earnings estimates, with analysts maintaining a "Moderate Buy" consensus and an average price target of $120.09. Meanwhile, company insiders have sold a significant amount of shares recently, totaling approximately $8.0 million over the past 90 days.
HC Wainwright Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price
HC Wainwright has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $130 to $158, maintaining a "buy" rating and suggesting a 40% upside. Despite a positive consensus from analysts, Weiss Ratings reiterated a "sell" rating. The company reported a quarterly loss of $0.90 per share, missing estimates, but revenue exceeded expectations.
DIANTHUS THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $158 FROM $130
H.C. Wainwright has increased its target price for Dianthus Therapeutics, Inc. (DNTH.O) to $158 from the previous $130. This update was reported by Reuters on August 6, 2026. The article highlights this specific financial analyst action regarding the biotechnology company.
DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125
Raymond James has raised its target price for DIANTHUS THERAPEUTICS INC (DNTH.O) from $125 to $131. The article, published by Reuters, provides this financial update without further detail or analysis.
Dianthus Therapeutics (NASDAQ:DNTH) Given New $122.00 Price Target at Wedbush
Wedbush has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) to $122.00 from $105.00, reiterating an "outperform" rating, which suggests a potential 10% upside. This comes despite the company missing quarterly EPS estimates with a loss of $0.90 per share, though revenue exceeded expectations. The stock currently holds a "Moderate Buy" consensus rating with an average target of $119.36 from analysts.
Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Misses Expectations By $0.05 EPS
Dianthus Therapeutics (NASDAQ:DNTH) reported a quarterly loss of $0.90 per share, missing analyst expectations by $0.05, despite revenue of $0.76 million exceeding the consensus estimate of $0.30 million. Following the announcement, shares rose 4.6% to $110.92. Analysts maintain a "Moderate Buy" rating with an average price target of $117.82, while company insiders have sold a significant number of shares recently.
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q2 License Revenue $761K
Dianthus Therapeutics, Inc. (DNTH) announced Q2 license revenue of $761K. The company is a clinical-stage biotechnology firm focused on therapies for severe autoimmune diseases, with its lead candidate, claseprubart, in Phase 3 trials. Analysts currently have a "BUY" consensus rating for DNTH with an average target price of $129.75.
Dianthus Therapeutics Q2 net loss widens as R&D costs rise
Dianthus Therapeutics reported a widened Q2 net loss of $50.2 million due to increased operating expenses, primarily driven by higher R&D costs for its clinical programs. Despite the loss, the company ended Q2 with $1.2 billion in cash, expected to fund operations into 2030, and anticipates several key clinical trial results by the end of 2026 and 2027. Analysts maintain a "strong buy" rating with a median price target of $125.00.
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
Dianthus Therapeutics has announced DNTH312, a new first-in-class, next-generation bifunctional fusion protein aimed at treating severe autoimmune diseases. This investigational drug combines claseprubart and TACI, targeting both active C1s and BAFF/APRIL pathways to provide comprehensive inhibition of B cell activity and Classical Pathway inflammation. DNTH312 has demonstrated comparable potency and half-life to existing treatments in preclinical studies and is expected to be Phase 1 ready by the end of 2027.
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Dianthus Therapeutics, Inc. has announced the issuance of inducement grants to six newly-hired, non-executive employees on August 3, 2026. These grants, approved by the Company's independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 87,000 shares of common stock with a 10-year term and an exercise price of $106.02 per share. This action aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent for the clinical-stage biotechnology company focused on autoimmune diseases.
Dianthus Therapeutics grants stock options to s...
Dianthus Therapeutics has granted 87,000 stock options to six new non-executive employees. These options, with a 10-year term and an exercise price of $106.02 per share, vest over four years and were approved under Nasdaq rules to incentivize new hires. Dianthus is a clinical-stage biotech company focusing on severe autoimmune diseases.
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Dianthus Therapeutics, Inc. announced the granting of equity awards to six new non-executive employees on August 3, 2026. These inducement grants, approved by the independent Compensation Committee, consist of non-qualified stock options for an aggregate of 87,000 shares of common stock with a 10-year term and an exercise price of $106.02 per share, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4).
Sei Investments Co. Acquires 78,388 Shares of Dianthus Therapeutics, Inc. $DNTH
Sei Investments Co. significantly increased its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 566.3%, acquiring an additional 78,388 shares in the first quarter, bringing its total to 92,229 shares valued at $7.74 million. Other institutional investors also adjusted their holdings, with several analysts reiterating "buy" or "outperform" ratings and setting an average target price of $117.82. The article also highlights recent insider selling activity and the company's financial performance.
Seven Fleet Capital Management LP Has $6.78 Million Holdings in Dianthus Therapeutics, Inc. $DNTH
Seven Fleet Capital Management LP significantly increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 451.6% in the first quarter, now owning 80,809 shares valued at $6.78 million. Despite this, company insiders have been selling shares, with executives offloading $7.99 million worth of stock in the last 90 days. Dianthus Therapeutics reported a smaller-than-expected quarterly loss of $0.85 per share and holds a "Moderate Buy" consensus rating from analysts with an average price target of $117.82.
DV Trading LLC Acquires Shares of 26,551 Dianthus Therapeutics, Inc. $DNTH
DV Trading LLC recently acquired 26,551 shares of Dianthus Therapeutics (NASDAQ:DNTH) valued at approximately $2.23 million. Despite a recent 5.1% drop in stock price, Dianthus Therapeutics reported better-than-expected quarterly losses, and analysts maintain a "Moderate Buy" rating with a target price of $117.82. However, company insiders have sold a significant amount of stock, totaling nearly $8 million, over the past 90 days.
Dianthus Therapeutics (Nasdaq:DNTH) - Stock Analysis
Dianthus Therapeutics (Nasdaq:DNTH) is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases. The company's stock has seen significant growth (399.2% in 1 year) but faces risks including past shareholder dilution and current unprofitability. Recent developments include the initiation of a Phase 3 trial for claseprubart in generalized myasthenia gravis, positive mid-stage results for chronic inflammatory demyelinating polyneuropathy (CIDP), and recent equity offerings to bolster its balance sheet.
Bank of New York Mellon Corp Purchases 113,280 Shares of Dianthus Therapeutics, Inc. $DNTH
Bank of New York Mellon Corp significantly increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 150.8% in the first quarter, acquiring an additional 113,280 shares to own a total of 188,412 shares valued at $15.8 million. Other institutional investors like Vanguard Group Inc. and UBS Group AG also boosted their holdings. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $117.82, and the company recently surpassed Q1 earnings estimates.
